nach oben

Erschienen in:

21.02.2020 | Epidemiology

Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases

verfasst von: Laurence Lambert-Côté, Anne-Déborah Bouhnik, Marc-Karim Bendiane, Cyril Bérenger, Myrto Mondor, Laetitia Huiart, Sophie Lauzier

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories.

Methods

We conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories.

Results

Among 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped.

Conclusion

Our results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals.

Nur mit Berechtigung zugänglich

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ (2019) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 37(5):423–438. https://doi.org/10.1200/jco.18.01160 CrossRefPubMed

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 32(21):2255–2269. https://doi.org/10.1200/jco.2013.54.2258 CrossRefPubMedPubMedCentral

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/S0140-6736(11)60993-8 CrossRef

Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138(1):325–328. https://doi.org/10.1007/s10549-013-2422-4 CrossRefPubMed

Murphy CC, Bartholomew LK, Carpentier MY (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478. https://doi.org/10.1007/s10549-012-2114-5 CrossRefPubMedPubMedCentral

Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691–705. https://doi.org/10.1111/j.1365-2125.2012.04167.x CrossRefPubMedPubMedCentral

Grégoire J-P, Moisan J (2016) Assessment of adherence to drug treatment in database research. In: Elseviers M, Wettermark B, Almarsdóttir AB, Andersen M, Benko R, Bennie M, Eriksson I, Godman B, Krska J, Poluzzi E, Taxis K, Vlahović-Palčevski V, Stichele RV (eds) Drug utilization research. Wiley, New York, pp 369–380. https://doi.org/10.1002/9781118949740.ch36 CrossRef

Vrijens B (2016) An introduction to adherence research. In: Elseviers M, Wettermark B, Almarsdóttir AB, Andersen M, Benko R, Bennie M, Eriksson I, Godman B, Krska J, Poluzzi E, Taxis K, Vlahović-Palčevski V, Stichele RV (eds) Drug utilization research. Wiley, New York, pp 355–360. https://doi.org/10.1002/9781118949740.ch34 CrossRef

McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ (2013) The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer 109(5):1172–1180. https://doi.org/10.1038/bjc.2013.464 CrossRefPubMedPubMedCentral

10.

Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537. https://doi.org/10.1007/s10549-010-1132-4 CrossRefPubMed

11.

Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524. https://doi.org/10.1038/bjc.2013.116 CrossRefPubMedPubMedCentral

12.

McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Clin Pharmacol 99(11):1763. https://doi.org/10.1038/sj.bjc.6604758 CrossRef

13.

Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD (2017) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence 11:305–322. https://doi.org/10.2147/ppa.s126651 CrossRefPubMedPubMedCentral

14.

Nagin D (2005) Group-based modeling of development. Harvard University Press, CambridgeCrossRef

15.

Nagin DS, Odgers CL (2010) Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6:109–138. https://doi.org/10.1146/annurev.clinpsy.121208.131413 CrossRefPubMed

16.

Nagin DS (2014) Group-based trajectory modeling: an overview. Ann Nutr Metab 65(2–3):205–210. https://doi.org/10.1159/000360229 CrossRefPubMed

17.

Franklin MJ, Shrank HW, Pakes SJ, Sanfélix-Gimeno AG, Matlin KO, Brennan KT, Choudhry KN (2013) Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care 51(9):789–796. https://doi.org/10.1097/MLR.0b013e3182984c1f CrossRefPubMed

18.

Franklin JM, Krumme AA, Tong AY, Shrank WH, Matlin OS, Brennan TA, Choudhry NK (2015) Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf 24(10):1105–1113. https://doi.org/10.1002/pds.3787 CrossRefPubMed

19.

Tervonen HE, Daniels B, Tang M, Preen DB, Pearson SA (2019) Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients. Pharmacoepidemiol Drug Saf. https://doi.org/10.1002/pds.4751 CrossRefPubMed

20.

Winn AN, Dusetzina SB (2016) The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf 25(8):953–959. https://doi.org/10.1002/pds.4012 CrossRefPubMed

21.

Institut national du cancer (2014) La vie deux ans après un diagnostic de cancer. De l’annonce à l’après cancer Collection Études et enquêtes edn, INCa

22.

Bouhnik A-D, Bendiane M-K, Cortaredona S, Sagaon Teyssier L, Rey D, Berenger C, Seror V, Peretti-Watel P (2015) The labour market, psychosocial outcomes and health conditions in cancer survivors: protocol for a nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey). BMJ Open. https://doi.org/10.1136/bmjopen-2014-005971 CrossRefPubMedPubMedCentral

23.

American Association for Public Opinion Research (2011) Standard definitions: final dispositions of case codes and outcome rates for surveys, 7th edn

24.

Institut national du cancer, Haute Autorité de santé (2010) Guide ALD 30—Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique—Cancer du sein. France

25.

Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N (2017) The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26(8):954–962. https://doi.org/10.1002/pds.4233 CrossRefPubMed

26.

Van Liew J, Christensen A, de Moor J (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8(3):521–531. https://doi.org/10.1007/s11764-014-0374-2 CrossRefPubMed

27.

Lambert LK, Balneaves LG, Howard AF, Gotay CC (2018) Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat 167(3):615–633. https://doi.org/10.1007/s10549-017-4561-5 CrossRefPubMed

28.

Cahir C, Guinan E, Dombrowski SU, Sharp L, Bennett K (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: a systematic review and meta-analysis. Patient Educ Couns 98(12):1524–1539. https://doi.org/10.1016/j.pec.2015.05.013 CrossRef

29.

Cortaredona S, Pambrun E, Verdoux H, Verger P (2017) Comparison of pharmacy-based and diagnosis-based comorbidity measures from medical administrative data. Pharmacoepidemiol Drug Saf 26(4):402–411. https://doi.org/10.1002/pds.4146 CrossRefPubMed

30.

Schwarz G (1978) Estimating the dimension of a model. Ann Stat 6(2):461–464. https://doi.org/10.1214/aos/1176344136 CrossRef

31.

Jones BL, Nagin DS, Roeder K (2001) A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res 29(3):374–393. https://doi.org/10.1177/0049124101029003005 CrossRef

32.

Librero J, Sanfelix-Gimeno G, Peiro S (2016) Medication adherence patterns after hospitalization for coronary heart disease. A population-based study using electronic records and group-based trajectory models (Research Article) (Report). PLoS ONE 11(8):e0161381. https://doi.org/10.1371/journal.pone.0161381 CrossRefPubMedPubMedCentral

33.

Lo-Ciganic W-H, Gellad WF, Gordon AJ, Cochran G, Donohue JM (2015) Associations between buprenorphine treatment trajectories and clinical outcomes in a large medicaid program. Drug Alcohol Depend 156:e132–e132. https://doi.org/10.1016/j.drugalcdep.2015.07.363 CrossRef

34.

Lo-Ciganic WH, Donohue JM, Kim JY, Krans EE, Jones BL, Kelley D, James AE, Jarlenski MP (2019) Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States. Pharmacoepidemiol Drug Saf 28(1):80–89. https://doi.org/10.1002/pds.4647 CrossRefPubMed

35.

Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD (2015) Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology 122(10):2010–2021. https://doi.org/10.1016/j.ophtha.2015.06.039 CrossRefPubMed

36.

Dillon P, Stewart D, Smith SM, Gallagher P, Cousins G (2018) Group-based trajectory models: assessing adherence to antihypertensive medication in older adults in a community pharmacy setting. Clin Pharmacol Ther 103(6):1052–1060. https://doi.org/10.1002/cpt.865 CrossRefPubMed

37.

Modi AC, Rausch JR, Glauser TA (2011) Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA 305(16):1669–1676. https://doi.org/10.1001/jama.2011.506 CrossRefPubMedPubMedCentral

38.

Klijn SL, Weijenberg MP, Lemmens P, van den Brandt PA, Lima Passos V, Balakrishnan N (2017) Introducing the fit-criteria assessment plot—a visualisation tool to assist class enumeration in group-based trajectory modelling. Stat Methods Med Res 26(5):2424–2436. https://doi.org/10.1177/0962280215598665 CrossRefPubMed

39.

Jones BL, Nagin DS (2013) A note on a stata plugin for estimating group-based trajectory models. Sociol Methods Res 42(4):608–613. https://doi.org/10.1177/0049124113503141 CrossRef

40.

Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128. https://doi.org/10.1200/jco.2009.25.9655 CrossRefPubMedPubMedCentral

41.

Kemp A, Preen D, Saunders C, Boyle F, Bulsara M, Malacova E, Roughead E (2014) Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice? SpringerPlus 3(1):1–10. https://doi.org/10.1186/2193-1801-3-282 CrossRef

42.

Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH-Y, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS (2014) Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol 32(22):2318. https://doi.org/10.1200/JCO.2013.51.7367 CrossRefPubMedPubMedCentral

43.

Danilak M, Chambers CR (2013) Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract 19(2):105–110. https://doi.org/10.1177/1078155212455939 CrossRefPubMed

44.

Font R, Espinas JA, Gil-Gil M (2012) Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer. https://doi.org/10.1038/bjc.2012.389 CrossRefPubMedPubMedCentral

45.

Wu J, Stafkey-Mailey D, Bennett CL (2012) Long-term adherence to hormone therapy in medicaid-enrolled women with breast cancer. Health Outcomes 3(4):e195–e203. https://doi.org/10.1016/j.ehrm.2012.10.001 CrossRef

46.

Hsieh K-P, Chen L-C, Cheung K-L, Yang Y-H (2015) Risks of nonadherence to hormone therapy in Asian women with breast cancer. Kaohsiung J Med Sci 31(6):328–334. https://doi.org/10.1016/j.kjms.2015.04.002 CrossRefPubMed

47.

Trabulsi N, Riedel K, Winslade N, Gregoire JP, Meterissian S, Abrahamovicz M, Tamblyn R, Mayo N, Meguerditchian A (2014) Adherence to anti-estrogen therapy in seniors with breast cancer: how well are we doing? Breast J 20(6):632–638. https://doi.org/10.1111/tbj.12328 CrossRefPubMed

48.

Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27(21):3445–3451. https://doi.org/10.1200/JCO.2008.19.2419 CrossRefPubMedPubMedCentral

49.

Brito C, Portela MC, de Vasconcellos MTL (2014) Adherence to hormone therapy among women with breast cancer. BMC Cancer 14:397. https://doi.org/10.1186/1471-2407-14-397 CrossRefPubMedPubMedCentral

50.

Brito C, Portela MC, de Vasconcellos MTL (2014) Factors associated to persistence with hormonal therapy in women with breast cancer. Rev Saude Publica 48(2):284–295. https://doi.org/10.1590/S0034-8910.2014048004799 CrossRefPubMedPubMedCentral

51.

Schmidt N, Kostev K, Jockwig A, Kyvernitakis L, Albert U, Hadji P (2014) Treatment persistence evaluation of tamoxifen and aromatase inhibitors in breast cancer patients in early and late stage disease. Int J Clin Pharmacol Ther 52(11):933–939. https://doi.org/10.5414/CP202172 CrossRefPubMed

52.

Brett J, Boulton M, Fenlon D, Hulbert-Williams NJ, Walter FM, Donnelly P, Lavery BA, Morgan A, Morris C, Watson EK (2018) Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence 12:291–300. https://doi.org/10.2147/ppa.S145784 CrossRefPubMedPubMedCentral

53.

Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23(4):882–890. https://doi.org/10.1093/annonc/mdr330 CrossRefPubMed

54.

Kahn KL, Schneider EC, Malin JL (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. https://doi.org/10.1097/01.mlr.0000257193.10760.7f CrossRefPubMed

55.

Hickson RP, Annis IE, Killeya-Jones LA, Fang G (2017) Comparing continuous and binary trajectory modeling: an example using real-world statin adherence data. In: International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, Canada, August 29 2017

Titel: Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases
verfasst von: Laurence Lambert-Côté
Anne-Déborah Bouhnik
Marc-Karim Bendiane
Cyril Bérenger
Myrto Mondor
Laetitia Huiart
Sophie Lauzier
Publikationsdatum: 21.02.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05549-x

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases